Ayurvedic wellness brand Kapiva has secured $60 million in its Series D funding round, representing a significant milestone in India’s traditional healthcare sector. This kapiva funding demonstrates strong investor confidence in the company’s ability to merge ancient Ayurvedic practices with modern wellness solutions for domestic and international markets.
Kapiva Series D Funding: $60 Million Investment Breakdown
The kapiva funding round comprises $28 million in primary capital and $32 million in secondary transactions. The funding round began in September 2024 when OrbiMed Asia, Vertex Ventures, and 3one4 Capital invested $10 million. The subsequent $50 million closure brings Kapiva’s total funding to nearly $90 million since inception. The primary capital of $28 million will support operations while the secondary portion enabled early investor Fireside Ventures to exit. The company’s valuation stands at Rs 1,450 crore as of September 2024, reflecting investor confidence in its growth trajectory and business fundamentals.
360 ONE Asset and Vertex Growth Lead Kapiva Investment
The kapiva funding round is co-led by 360 ONE Asset and Vertex Growth, with participation from existing investors. 360 ONE Asset, formerly IIFL Wealth, brings extensive financial resources and consumer brand scaling expertise. Vertex Growth specializes in technology-enabled consumer businesses and growth-stage investments. OrbiMed Asia, Vertex Ventures, and 3one4 Capital continue as participating investors, demonstrating sustained confidence in the company’s direction. These institutional investors provide not just capital but strategic guidance, operational expertise, and access to distribution networks essential for scaling operations across multiple markets.
Fireside Ventures Exit: What It Means for Kapiva
Early investor Fireside Ventures exited through the $32 million secondary transaction component of this kapiva funding round. As an early-stage consumer-focused venture firm, Fireside Ventures played a crucial role in establishing Kapiva’s initial market position and brand foundation. This exit represents a natural progression in startup lifecycle dynamics, where early-stage funds realize returns after helping companies achieve operational maturity. The transition creates space for growth-stage investors with longer investment horizons better suited for Kapiva’s international expansion phase. The successful execution of this secondary sale demonstrates market attractiveness, as new investors were willing to provide liquidity while simultaneously contributing primary growth capital.
Kapiva’s International Expansion Plans After Funding
The kapiva funding will support research and development, manufacturing expansion, brand building, and strengthening the health tech platform. The company has established a wholly-owned US subsidiary, Kapiva Inc., signaling serious commitment to international markets including North America, Europe, and the Middle East. The $28 million primary capital will enable product formulation development meeting international regulatory standards while maintaining Ayurvedic authenticity. Manufacturing capacity expansion will accommodate anticipated international demand without compromising quality standards. Technology investments will enhance the company’s digital health platform, creating differentiation through personalized wellness recommendations integrated with traditional Ayurvedic consultations, establishing competitive advantages beyond product offerings alone.
Ayurvedic Wellness Brand Kapiva Nears Profitability
The company is approaching profitability, having demonstrated strong growth fundamentals. Kapiva currently operates at an annual revenue run rate of Rs 550 crore, up from approximately Rs 350 crore in FY25. The company’s annual revenue reached Rs 234 crore as of March 31, 2024. This financial performance distinguishes Kapiva in the competitive D2C landscape where many brands prioritize growth over sustainable unit economics. The path to profitability is significant given the capital-intensive nature of wellness and healthcare industries requiring substantial investments in quality assurance, regulatory compliance, and scientific validation. This kapiva funding positions the company to achieve profitability while simultaneously expanding internationally, demonstrating mature business fundamentals and operational efficiency essential for long-term success.
business model of KAPIVA
| Category | Details |
|---|---|
| How Company Started | Founded in 2016 by Ameve Sharma and Shrey Badhani, Kapiva emerged from Ameve’s family legacy (grandson of Baidyanath Group founder). Initially focused on traditional Ayurvedic clinics before pivoting to functional foods and wellness products. Started with Ayurvedic juices to deliver nutrition in modern formats, establishing a D2C model targeting health-conscious millennials. |
| Present Condition | Strong financial trajectory with Rs 550 crore annual revenue run rate and Rs 234 crore revenue in FY24. Total funding of ~$90 million across multiple rounds. Leadership includes co-founders Shrey Badhani and Ameve Sharma, with Shantanu and Nicholas Kelley as CEOs. Current valuation stands at Rs 1,450 crore (September 2024). Established presence across 150+ retail outlets and major e-commerce platforms including Amazon, 1mg, and BigBasket. |
| Future of Company & Industry | Indian Ayurvedic products market projected to reach INR 3,605 billion by 2033, growing at 16.17% CAGR. India’s Ayurvedic wellness market expected to reach $42.2 billion by 2033. Kapiva is expanding internationally through US subsidiary (Kapiva Inc.) targeting North America, Europe, and Middle East. Focus on achieving profitability while scaling operations and strengthening health tech platform for personalized wellness solutions. |
| Opportunities for Young Entrepreneurs | Growing consumer preference for natural, chemical-free wellness solutions creates massive opportunity. D2C model enables direct customer relationships without heavy retail infrastructure. Technology integration with traditional knowledge systems presents innovation potential. Export opportunities as global Ayurveda market grows at 27% CAGR. White spaces in specialized categories like immunity, gut health, and personalized nutrition using Ayurvedic principles. |
| Market Share | Kapiva competes in fragmented D2C Ayurveda space with players like MyUpchar, OZiva, Piramal’s Lacto Calamine, and legacy brands like Dabur, Himalaya, and Patanjali. With Rs 550 crore revenue in market approaching Rs 87,590 crore (2024), Kapiva holds approximately 0.6% market share with potential for significant growth as organized players gain traction. |
| MOAT (Competitive Advantage) | Heritage + Innovation: Founder’s connection to Baidyanath legacy provides authentic Ayurvedic credibility while modern D2C approach attracts younger consumers. Health Tech Integration: Technology platform offering personalized consultations differentiates from pure product sellers. Quality & Certification: Focus on organic, scientifically validated formulations meeting international standards. Omnichannel Presence: Strong online + offline distribution across multiple platforms provides resilience. |
| How Company Makes Money | Revenue streams from direct product sales through e-commerce platform and online retailers, partnerships, and brand collaborations. Multi-channel strategy includes own website, Amazon, Flipkart, health platforms (1mg), grocery platforms (BigBasket), and 150+ physical retail outlets. Product categories span juices, teas, oils, supplements, and functional foods addressing hair fall, weight management, digestion, diabetes, and general wellness. Export sales to international markets add additional revenue stream. |
My Name is Adarsh and I am Empowering startups with high-quality content at Startups Union and bridging the gap between brand stories.
